
    
      The study is a multicentre randomised clinical trial involving 110 patients with a risky
      alcohol intake (exceeding 21 alcohol units (252 g ethanol) per week or/ and daily smoking
      scheduled for bladder cancer surgery. Patients will be randomised to the 6-weeks GSP or
      treatment as usual (control). The GSP combines patient education and pharmacologic
      strategies. The GSP includes benzodiazepine therapy for withdrawal symptoms, controlled
      disulfiram therapy, and Nicotine replacement.
    
  